Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
Date:10/27/2008

e soluble and membrane-bound forms of TNF- alpha.

Centocor discovered golimumab and has exclusive marketing rights to the product in the United States. Pending regulatory approval, Schering-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and China where golimumab will be exclusively marketed by Xian-Janssen.

About Centocor

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor is a wholly-owned subsidiary of Johnson & Johnson.

CENTOCOR DISCLOSURE NOTICE: This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Centocor's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... , , ... the world,s preeminent cord blood banks, today announced that Shannon Miller ... endorsement partnership agreement and will appear in a series of advertising and ... http://www.newscom.com/cgi-bin/prnh/20090528/NY23885LOGO ) , , Considered "The ...
... NATICK, Mass., Aug. 24 Boston Scientific Corporation (NYSE: ... from the landmark MADIT-CRT trial on Tuesday, September 1, at 8:00 ... , The call will be hosted by Ray Elliott, ... Group President, Cardiac Rhythm Management; and Arthur Moss, M.D., Professor of ...
... BOZEN, Italy, August 24 ... of its recent partnership announcement with McKesson, it,has ... 13 North American,customers in just a few days ... hospital policies prevent them from publicly,commenting on industry ...
Cached Biology Technology:7-Time Olympic Medalist Shannon Miller Endorses StemCyte 2Boston Scientific to Webcast Conference Call Discussing Results of Landmark MADIT-CRT Trial 2Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 2Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 3Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 4
(Date:4/23/2014)... of Public Health-Bloomington has bolstered the link between red ... association between heme iron, found only in meat, and ... that heme iron consumption increased the risk for coronary ... found between nonheme iron, which is in plant and ... study was published online ahead of print in the ...
(Date:4/23/2014)... Toronto Scarborough research shows that male black widow spiders ... a rare example of mate preference by male spiders. ... Emily MacLeod and Maydianne Andrade, a professor in UTSC,s ... studies and the wild that males overwhelmingly chose to ... black widows can tell whether a potential mate is ...
(Date:4/23/2014)... of an accurate group decision increases with the abundance ... collective faces a variety of factors as often ... report that smaller groups actually tend to make more ... on only certain pieces of information. , The findings ... collective intelligence, or the "wisdom of crowds," wherein individual ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... A multidisciplinary clinical practice guideline, "Tonsillectomy in Children" will ... and Neck Surgery (watch for a new cover ... new guideline provides evidence-based recommendations on the pre-, intra-, ... to 18 years under consideration for tonsillectomy. Additionally, this ...
... dominant natural process of new species formation and trigger ... in the journal PLoS ONE . The ... to 375 million years ago suggests that the planet,s ... meet a similar fate. Although Earth has experienced ...
... provide a significant source of revenue in southern ... during the holiday buying season. The most popular ... for its fragrance and consumer-friendly traits such as ... natural Christmas tree shape. Frasers, indigenous to isolated ...
Cached Biology News:Tonsillectomy in children 2What triggers mass extinctions? Study shows how invasive species stop new life 2What triggers mass extinctions? Study shows how invasive species stop new life 3April grafting optimal for Fraser fir 2
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
...
Biology Products: